Other New Products

BPCA/Pediatric Exclusivity Statistics: List of Determinations Including Written Request (updated)

BPCA/Pediatric Exclusivity Statistics: List of Determinations Including Written Request (updated)

Drug Safety Oversight Board Meeting, March 20, 2008 Public Summary

Drug Safety Oversight Board Meeting, March 20, 2008 Public Summary

Prescription Drug User Fee Act (PDUFA) Billable Products

Prescription Drug User Fee Act (PDUFA) Billable Products (updated)

Enbrel (etanercept)

Prescribing information revised to include a BOXED WARNING regarding the risk of infection including tuberculosis.

Guidance for Industry

Comprehensive List of Guidance Documents

Guidance for Industry

New/Revised/Withdrawn List for 2008

Common Technical Document (CTD) Modules/Sections Corresponding to Summary Data Tables in Bioequivalence Submissions to ANDAs (up

Common Technical Document (CTD) Modules/Sections Corresponding to Summary Data Tables in Bioequivalence Submissions to ANDAs (updated)

FDA Approves Amitiza for IBS-C

The U.S. Food and Drug Administration has approved Amitiza (lubiprostone) for the treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in adult women aged 18 and over.

Medical, Statistical, and Clinical Pharmacology Reviews of Pediatric Studies

Medical, Statistical, and Clinical Pharmacology Reviews of Pediatric Studies Conducted under Section 505A and 505B of the FDA (the Act), as amended by the FDA Amendments Act of 2007 (FDAAA)

Drug News and Information

New Products

Syndicate content